title: Outcomes of pregnancy in women with autoimmune hepatitis.
abstract: BACKGROUND
  Optimal management during pregnancy of patients with autoimmune hepatitis (AIH) remains undefined. We therefore reviewed all patients with AIH who reported pregnancy at our centre to identify any pre-conception factors that might predict adverse outcomes.
  
  
  RESULTS
  There were 81 pregnancies in 53 women. Median age at conception was 26 years (range 16-42); with 41% of pregnancies occurring in the context of cirrhosis. At conception, 61 patients (75%) were on therapy for AIH. The live birth rate (LBR) was 73% (59/81). Prematurity, occurred in 12/59 (20%) and 6 (11%) required admission to special care baby unit (SCBU). In mothers who were cirrhotic at the time of conception the LBR was lower (p = 0.02) and need for admission to SCBU was higher. The overall maternal complication rate was 31/81 (38%) conceptions. A flare in disease activity occurred in 26/81 (33%) pregnancies. A serious maternal adverse event (death or need for liver transplant) during or within 12-months of delivery, or hepatic decompensation during or within 3-months of delivery, occurred with 9 pregnancies (11%) and was more common in women with cirrhosis (p = 0.028). Maternal therapy had no significant impact on the LBR (p = 0.24), termination rate (p = 0.72), miscarriage rate (p = 0.19) or gestational period (p = 0.8). Flares in AIH were more likely in patients who were not on therapy (p = 0.048) or who had a disease flare in the year prior to conception (p = 0.03). Patients who had a flare in association with pregnancy were more likely to decompensate from a liver standpoint (p = 0.01).
  
  
  CONCLUSIONS
  This study demonstrates that poor disease control in the year prior to pregnancy and the absence of drug therapy are associated with poor outcomes whist pregnant. These data should facilitate appropriate pre-conception counselling and appropriate pregnancy management in this cohort.
authors.affiliation: Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom. rachel.westbrook@nhs.net
authors.forename: Rachel H
authors.initials: RH
authors.lastname: Westbrook
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Yeoman
authors.forename: Stephen
authors.initials: S
authors.lastname: Kriese
authors.forename: Michael A
authors.initials: MA
authors.lastname: Heneghan
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005306:Fertilization; D005355:Fibrosis / Q000209:etiology; D019693:Hepatitis, Autoimmune / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy / Q000187:drug effects / Q000276:immunology*; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011379:Prognosis; D027724:Reproductive Techniques, Assisted; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents